| Clinical and echocardiographic follow-up of patients previously treated with dexfenfluramine or phentermine/fenfluramine. | |
| | |
MedLine Citation:
|
PMID: 11667938 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
CONTEXT: Use of anorexigen therapy is associated with valvular abnormalities, although there is limited information on long-term changes in valvular regurgitation following discontinuation of these agents. OBJECTIVE: To evaluate changes in valvular regurgitation, valve morphology, and clinical parameters 1 year after an initial echocardiogram in patients previously treated with dexfenfluramine or phentermine/fenfluramine and in untreated controls. DESIGN AND SETTING: A reader-blinded, multicenter, echocardiographic and clinical 1-year follow-up study at 25 outpatient clinical sites. PATIENTS: A total of 1142 obese patients (1466 participated in the initial study) who had follow-up echocardiogram; all but 4 had a follow-up medical history and physical examination. Follow-up time from discontinuation of drug to follow-up echocardiogram for 371 dexfenfluramine patients was 17.5 months (range, 13-26 months) and for 340 phentermine/fenfluramine patients was 18.7 months (range, 13-26 months) after discontinuation of drug therapy. MAIN OUTCOME MEASURE: Change in grade of valvular regurgitation and valve morphology and mobility. RESULTS: Echocardiographic changes in aortic regurgitation were observed in 8 controls (7 [1.7%] had decreases; 1 [0.2%] had an increase); 29 dexfenfluramine patients (23 [6.4%] had decreases; 6 [1.7%] had increases; P<.001 vs controls); and 15 phentermine/fenfluramine patients (4.5% all decreases; P =.03 vs controls). No statistically significant differences were observed when treated patients were compared with controls for changes in medical history, physical findings, mitral regurgitation, aortic or mitral leaflet mobility or thickness, pulmonary artery systolic pressure, ejection fraction, valve surgery, or cardiovascular events. CONCLUSION: Progression of valvular abnormalities is unlikely in patients 1 year after an initial echocardiogram and 13 to 26 months after discontinuation of dexfenfluramine and phentermine/fenfluramine. |
| | |
Authors:
|
J M Gardin; N J Weissman; C Leung; J A Panza; D Fernicola; K D Davis; G D Constantine; C L Reid |
Related Documents
:
|
10456408 - Long term results of mitral valve repair: posterior papillary muscle repositioning vers... 12892458 - Late results of mitral valve repair for mitral regurgitation. 12352348 - Urethral mobilization and advancement for midshaft to distal hypospadias. 9731088 - An assessment of heart-valve abnormalities in obese patients taking dexfenfluramine, su... 11472348 - Safety and efficacy of thalidomide in patients with myelofibrosis with myeloid metaplasia. 12696998 - Preventative treatment for migraine and tension-type headaches : do drugs having effect... |
Publication Detail:
|
Type: Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: JAMA : the journal of the American Medical Association Volume: 286 ISSN: 0098-7484 ISO Abbreviation: JAMA Publication Date: 2001 Oct 24-31 |
Date Detail:
|
Created Date: 2001-10-22 Completed Date: 2001-12-04 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 7501160 Medline TA: JAMA Country: United States |
Other Details:
|
Languages: eng Pagination: 2011-4 Citation Subset: AIM; IM |
Affiliation:
|
Division of Cardiology, St John Hospital and Medical Center, 22201 Moross Rd, PB II, Suite 470, Detroit, MI 48236, USA. julius.gardin@stjohn.org |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Aged Aortic Valve Insufficiency / chemically induced, ultrasonography Appetite Depressants / adverse effects* Central Nervous System Stimulants / adverse effects* Dexfenfluramine / adverse effects* Echocardiography Female Fenfluramine / adverse effects* Follow-Up Studies Heart Valve Diseases / chemically induced*, ultrasonography* Humans Logistic Models Male Middle Aged Mitral Valve Insufficiency / chemically induced, ultrasonography Obesity / drug therapy Phentermine / adverse effects* Serotonin Agents / adverse effects* |
| Chemical | |
Reg. No./Substance:
|
0/Appetite Depressants; 0/Central Nervous System Stimulants; 0/Serotonin Agents; 122-09-8/Phentermine; 3239-44-9/Dexfenfluramine; 458-24-2/Fenfluramine |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Universal newborn hearing screening: summary of evidence.
Next Document: The distributed annotation system.